MREO

UK-based biopharmaceutical company developing therapies for rare diseases with significant unmet need. Pipeline includes treatments for osteogenesis imperfecta, oncology, and respiratory conditions. Focuses on reformulation, repurposing, and rescue of existing clinical assets to accelerate development timelines.